Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.05 USD | +3.29% | +1.19% | +23.41% |
Financials (USD)
Sales 2024 * | 535M | Sales 2025 * | 576M | Capitalization | 1.38B |
---|---|---|---|---|---|
Net income 2024 * | 23M | Net income 2025 * | 34M | EV / Sales 2024 * | 2.58 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.4 x |
P/E ratio 2024 * |
52.5
x | P/E ratio 2025 * |
33
x | Employees | 642 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.64% |
Latest transcript on ANI Pharmaceuticals, Inc.
1 day | +3.29% | ||
1 week | +1.40% | ||
Current month | +3.11% | ||
1 month | +1.49% | ||
3 months | +20.42% | ||
6 months | +30.24% | ||
Current year | +23.41% |
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
David Nash
BRD | Director/Board Member | 68 | 18-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 68.05 | +3.29% | 305,694 |
24-05-09 | 65.88 | +0.40% | 187,936 |
24-05-08 | 65.62 | -1.65% | 161,262 |
24-05-07 | 66.72 | -0.95% | 149,589 |
24-05-06 | 67.36 | +0.16% | 116,785 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.41% | 1.38B | |
+30.38% | 695B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 330B | |
+3.73% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+7.68% | 168B |
- Stock Market
- Equities
- ANIP Stock